Syndax (SNDX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$252.3M

Revenue (quarter)

$72.8M

Revenue growth (year over year)

+91.76%

Gross profit (trailing twelve months)

$241.6M

Gross margin

95.78%

Net income (trailing twelve months)

−$220.8M

Net income (quarter)

−$49.4M

Net income growth (year over year)

+31.29%

Net margin

−87.52%

Return on equity

−255.93%

EPS (trailing twelve months)

−$2.51

Book value per share

$0.17

P/E (trailing twelve months)

—

Price to book

80.02

Debt to assets

97.85%

Payout ratio

—

Dividend yield

—

Company profile

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

• Is Syndax (SNDX) profitable?

  No. Syndax reported a net loss of $220.8M over the trailing twelve months.

• How much revenue does Syndax (SNDX) make?

  Syndax generated $252.3M in revenue over the trailing twelve months, up 91.76% year over year.

• How do I buy stock in Syndax (SNDX)?

  SNDX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.